In the present study a complex of the general formula [Ru(DCQX)(CO)2(EtO)]2complex, (where DCQX and EtO are 6,7- dichlorolquinoxaline- 2,3-dione and ethoxo), was synthesized in one step starting with the reaction of Ru3(CO)12 with DCQX ligand. Initia
DOI:
https://doi.org/10.59743/jbs.v25i.155Keywords:
Quinoxaline, ruthenium complex, Metal carbonyl and Biological activityAbstract
In the present study a complex of the general formula [Ru(DCQX)(CO)2(EtO)]2complex, (where DCQX and EtO are 6,7- dichlorolquinoxaline- 2,3-dione and ethoxo), was synthesized in one step starting with the reaction of Ru3(CO)12 with DCQX ligand. Initial characterization based on the elemental and mass analysis has suggested one structure (Fig. 3). The IR studies were useful in assigning the coordination modes of the ligands especially in the carbonyl region of the spectrum (Fig.2). The high-intensity bands in the UV region of the spectrum may be assigned to the QX(O-p)→Ru(eg) and EtO(O-p)→Ru(eg) LMCT transitions and/or Ru(t2g)→(CO) MLCT transition(Fig. 6). The thermogravimetric analysis gave more insight into the composition and the thermal stability of the complex( Table 2).Although, both DCQX ligand and the molybdenum complex showed antimicrobial activities, the complex inhibition to the studied microorganisms was higher.
References
B. Lippert, Cisplatin. Chemistry and Biochemistry of a Leading
Anticancer Drug, VerlagHelvetica Chimica. Acta, Zurich, Wiley- VCH, Weinheim, 1999.
M. A. Jakupec,M. Galanski, B. K. Keppler, Rev. Physiol. Biochem. Pharmacol.146 (2003) 1-53.
M. J. Clarke, Coord. Chem. Rev. 236 (2003) 209-233. [4] C. S. Allardyce, P. J. Dyson, Plat. Met. Rev.45 (2001) 62-69.
C. G. Hartinger, A. D. Phillips, A. A. Nazarov, Curr. Top. Med. Chem. 21 (2011) 2688-2702.
A. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris,
H. Chen, P. J. Sadler, H. Jodrell, Br. J. Cancer 86(2002) 1652- 1657.
H. Thakuria, G. Das, J. Chem. Sci. 118 (2006) 425. [8] F. Dianzhong, M.Wang, B.Wang, Polyhedron 11 (1992) 1109. [9] P. A. Wicklund, D. G. Brown, Inorg. Chem 15 (1976) 396-401. [10] D. G. Brown, W. L. Johnson, Z. Naturforsch. 34B (1979)712-
A. S. Attia, Polyhedron 26 (2007) 2550-2558. [12] C. S. Wu, G. R. Rossman, H. B. Gray, G. S. Hammond, H. J. Schugar, Inorg. Chem. 11 (1972) 990-994. [13] M. Mikuriya, D. Yoshioka, M. Handab, Coord. Chem. Rev. 250 (2006)
–221.
W. Wang, X. Liu, D. Liao, Z. Jiang, S. Yan, G. Wang, Inorg. Chem. Comm. 5 (2002) 1007–1011. [15] G. Ertepinarl, Y. Gok, O. Geban, S. Ozden, Eur. J. Med. Chem. 30 (1995) 171-175. [16] Attia S. Attia , Ayman A. Abdel Aziz, Khalifa A. Alfallous, M.F.El-
Shahat,Polyhedron 51 (2013) 234-254.
K.N. Raymond, S. S. Isied, L. D. Brown, F. R. Fronczek, J. H. Nibert, J. Am. Chem. Soc., 98 (1976) 1767-1774. [18] A.Khalafi-Nezhad, M. N. Soltani Rad, H. Mohalbatkar, Z. Asrsri, B.
Hemmateenejad, Bioorg. Med. Chem. 13 (2005) 1931-1938.
A.K. Ghose, A. Pritchet, G. M. Crippen, J. Comput. Chem. 9 (1988) 80-90. [20] F. A. Peacock, P. J. Sadler Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Chem.Asian. J. 3 (2008) 1890–1899.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 Journal of Basic Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
